Crinetics Pharmaceuticals, Inc.
General ticker "CRNX" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $3.8B (TTM average)
Crinetics Pharmaceuticals, Inc. follows the US Stock Market performance with the rate: 28.6%.
Estimated limits based on current volatility of 4.7%: low 30.48$, high 33.46$
Factors to consider:
- Price in estimated range
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [29.52$, 64.93$]
- 2025-12-31 to 2026-12-31 estimated range: [18.39$, 43.28$]
Financial Metrics affecting the CRNX estimates:
- Negative: Non-GAAP EPS, $ of -3.71 <= 0.04
- Negative: negative Operating income
- Negative: Industry operating cash flow per share per price (median), % of -21.10 <= 2.82
- Negative: Operating cash flow per share per price, % of -4.77 <= 1.79
- Negative: negative Industry operating income (median)
- Negative: negative Net income
- Positive: Interest expense per share, $ of 0 <= 0
Short-term CRNX quotes
Long-term CRNX plot with estimates
Financial data
YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
---|---|---|---|
Operating Revenue | $4.74MM | $4.01MM | $1.04MM |
Operating Expenses | $172.62MM | $226.62MM | $339.89MM |
Operating Income | $-167.88MM | $-222.61MM | $-338.85MM |
Non-Operating Income | $3.96MM | $8.08MM | $40.45MM |
Interest Expense | $4.32MM | $0.00MM | $0.00MM |
R&D Expense | $130.22MM | $168.53MM | $240.16MM |
Income(Loss) | $-163.92MM | $-214.53MM | $-298.41MM |
Profit(Loss)* | $-159.95MM | $-214.53MM | $-298.41MM |
Stockholders Equity | $316.33MM | $539.11MM | $1,324.81MM |
Assets | $352.18MM | $635.35MM | $1,434.59MM |
Operating Cash Flow | $-115.20MM | $-166.31MM | $-225.97MM |
Capital expenditure | $1.66MM | $4.69MM | $3.84MM |
Investing Cash Flow | $-173.98MM | $-200.41MM | $-574.82MM |
Financing Cash Flow | $121.96MM | $388.94MM | $1,010.43MM |
Earnings Per Share** | $-3.08 | $-3.69 | $-3.69 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.